Connect with us

CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App



Reading Time: 3 minutes

Results Confirm the Efficacy of CureApp’s Nicotine Dependence
Treatment Application

TOKYO–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#ClinicalTriallt;/agt;–Results from the world’s first randomized control study to examine
digital therapeutic smoking cessation programs were presented on May 20th
at the American Thoracic Society International Conference. The findings
demonstrate that CureApp’s nicotine dependence treatment app resulted in
an improvement in continuous abstinence rate (CAR) compared to a control
group over multiple time points.

Kohta Satake, M.D., M.B.A., M.P.H., Chief Executive Officer of CureApp,
and a respiratory specialized physician says, “Healthcare
professionals are challenged to help patients fight against the
psychological nicotine addiction alone between clinical visits.
CureApp’s digital therapeutics approach is a breakthrough in bridging
the gap between clinical visits providing daily support to the patients.
We are striving for regulatory and reimbursement approval to deliver the
solution as soon as possible.”

The CureApp solution delivers information and educational material
through an app that is conveniently on the patient’s smartphone,
together with a Carbon Monoxide (CO) monitor for tracking their
progress, and a web interface for physicians. CureApp’s system is the
first such program to undergo the rigorous testing of Phase III clinical
trials. With this confirmation of its efficacy, CureApp’s goal is to use
this data to obtain regulatory approval and health insurance coverage in
Japan and to expand globally in multiple countries including the United

Nicotine dependence

Nicotine dependence is a type of drug dependence; its intensity has been
reported to be comparable to that of heroin and cocaine*1.
Smoking is the Number 1 leading cause of preventable death in Japan*2
and the US*3.

The Clinical Trial

CureApp’s Phase III clinical trial in Japan was completed in December
2018, and the results were presented at the America Thoracic Society
International Conference, ATS 2019 by Dr. Hiroki Tateno, Division of
Pulmonary Medicine, Department of Medicine, Keio University, School of

The continuous abstinence rate (CAR)* at 9 to 24 weeks, the primary
endpoint to verify the efficacy of the CureApp Smoking Cessation, was
statistically significantly higher in the trial treatment group than the
control group, demonstrating that the CureApp Smoking Cessation
contributed to continuous smoking abstinence.

*Continuous abstinence rates at 9 to 24 weeks: Rates of patients who
continuously abstained from smoking at 9 to 24 weeks after the start of
smoking cessation treatment

The clinical trial was a multicenter, randomized, prospective, two-group
comparative study of the efficacy and safety of the CureApp Smoking
Cessation in combination with the standard smoking cessation treatment
program in patients with nicotine dependence who visited a smoking
cessation clinic. In this clinical trial, the CureApp Smoking Cessation
(smartphone application for patients, portable CO checker for patients,
and web-based application for physicians) or control device (the control
group application) was used for 24 weeks in addition to the standard
smoking cessation program.

Of the 584 patients who participated in this trial, 285 patients were
assigned to the treatment group using the application for nicotine
dependence treatment, 287 patients were assigned to the control group
using the control application. Total of 572 patient data was used for
analysis. The main evaluation item is “Continuous Abstinence Rate (CAR)
at Week 9-24”.


The CAR at 9 to 24 weeks, the primary endpoint, was 63.9% (182/285
subjects) in the trial treatment group and 50.5% (145/287) in the
control group. The CAR was higher by 13.4% in the trial treatment group,
showing a statistically significant difference (95% confidence interval,
1.239-2.424; P = 0.001), with an odds ratio of 1.73. The result
demonstrates that the CureApp Smoking Cessation contributed to
continuous smoking abstinence.

*1 Source: Kinen no Igaku (Medicine of Smoking Cessation), Japan
Medical Association

*2 Source: Adult Mortality Attributable to Preventable Risk Factors for
Noncommunicable Diseases and Injuries in Japan in 2007, the Ministry of
Health, Labour and Welfare

*3 Source: Health Effects of Cigarette Smoking, CDC

About CureApp

CureApp, Inc., a MedTech venture company, engages in research and
development to create and market medical programs and devices for
disease treatment with advanced software technology and medical
evidence. Its pioneering work in digital therapeutics will bring new
solutions for a variety of conditions, including nicotine addiction,
diabetes, and hypertension amongst others.

Currently, CureApp is jointly developing a nicotine dependence treatment
solution with the Division of Pulmonary Medicine, Keio University,
School of Medicine (clinical trial completed), a non-alcoholic
steatohepatitis (NASH) treatment solution with the University of Tokyo
Hospital (clinical trial in progress), and a hypertension treatment
solution with Cardiovascular Medicine, Jichi Medical University
(clinical trial in progress).

By leveraging the knowledge and findings accumulated in the development
of these treatment applications for medical institutions, CureApp
provides mobile health programs for private corporations and health
insurance associations, including the “ascure Smoking Cessation Program”
and “ascure STEPS Lifestyle Habit Improvement Program.” CureApp plans to
expand these and other digital therapeutic solutions from Japan to the
global market. For more information visit,


For US media
Joy Scott, CEO, Scott
Public Relations

For media from other countries
Daime, Public Relations Manager, CureApp, Inc.


Oppenheimer & Co. To Host 19th Annual Consumer Growth and E-Commerce Conference



Reading Time: 2 minutes


Oppenheimer & Co. Inc. (“Oppenheimer”) – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – will host its 19th Annual Consumer Growth and E-Commerce Conference on June 18-19 in Boston, MA. This year’s event features companies from prominent consumer brands such as Autozone, Domino’s Pizza, Express, Home Depot, Lowe’s, Six Flags Theme Parks, Tiffany & Company, Ulta, Walmart, Weight Watchers, and Yum Brands.

Of particular note, Oppenheimer is pleased to host nine of the market-leading companies involved with emerging trends in the Cannabis space this year. The event will also feature seven panel discussions, moderated by Oppenheimer Consumer Research Analysts, addressing emerging and disruptive trends in the consumer marketplace as follows:

  • Evolving Role of Technology in the Consumer Sector with Cooler Screens and Lindsay Goldberg LLC, moderated by Brian Nagel
  • A Discussion with Emerging Restaurant Brands with Aurify and B. Good, moderated by Brian Bittner
  • A Discussion on the Evolving US Food & Beverage Landscape with Lifeway, New Age Beverage, and United Natural Foods, moderated by Rupesh Parikh
  • Next Gen Brands Re-Shaping Landscape for Women’s Fashion with CARAA and Rothy’s, moderated by Brian Nagel
  • Exciting New Brands Shaking Up Home Products Space with Burkelman, LoveSac and Resident/Nectar, moderated by Brian Nagel
  • A Discussion on the Emerging CBD Landscape with Curaleaf and CV Sciences, moderated by Rupesh Parikh
  • Leveraging the Power of Digital to Connect with Consumers with Eight and FlexShopper, moderated by Brian Nagel

The conference features Oppenheimer’s Consumer Senior Research Analysts:

  • Brian Bittner, Managing Director Senior Analyst covering Restaurants
  • Brian Nagel, Managing Director and Senior Analyst covering Retail and E-Commerce
  • Rupesh Parikh, Managing Director and Senior Analyst covering Food, Grocery and Consumer Products
  • Ian Zaffino, Managing Director and Senior Analyst covering event-driven Special Situations

“Long-established business models are being upended by disruptive brands and technology, affecting consumer preferences and buying behaviors throughout the consumer industry. This year’s event aims to showcase the mix of market-leading and emerging companies driving and navigating these changes,” said Erica L. Moffett, Managing Director and Associate Director of Research at Oppenheimer. “From effortless payment methods to accelerated delivery times and customized products, consumers want a seamless experience. In order to succeed, companies must stay current on the evolving consumer and we are pleased to host a conference to explore this new landscape.”

Oppenheimer’s next conference will be the Montauk Emerging Life Sciences Summit, which will be held on June 26-28in Montauk, NY. The 22nd Annual Technology, Internet & Communications Conference will follow on August 6-7 in Boston, MA, followed by the Midwest Corporate Access Day in Chicago on August 15.

Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

SOURCE Oppenheimer & Co. Inc.

Continue Reading


iCAN: Israel-Cannabis CEO and Founder Saul Kaye to Participate at the World Cannabis Congress in Saint John, New Brunswick



Reading Time: 1 minute


iCAN: Israel Cannabis Founder and CEO Saul Kaye will participate at the World Cannabis Conference being held in Saint John, New Brunswick, Canada from June 16-18, 2019.

Kaye, a leader in the global cannabis ecosystem will moderate a session entitled, “Innovative Methodologies and Emerging Topics in Global Cannabis Research.”  Panelists are Dr. Suzanne Sisley MD President and Principal Investigator, Scottsdale Research Institute and, Dr. Jerry King, R&D Consultant, CFS.  The session will take place at the Saint John Trade & Convention Centre on June 18.

The World Cannabis Congress (WCC) is an exclusive, invite-only event for international cannabis leaders, influencers and trend setters. The event will have hundreds of attendees from around the world from business, government and medicine.

In addition to his leadership of iCAN: Israel Cannabis, Kaye is an industry advisor to the Medical Cannabis Caucus of the Israeli Parliament, as well as an advisor to the Ministries of Economy and Health in Israel. He is a licensed pharmacist and a successful entrepreneur with both retail and e-commerce experience. Saul has founded multiple companies spanning six countries across the US, EuropeIsrael and Australia.

Canada has truly been a global trailblazer in the cannabis industry.  Canadian cannabis companies and its stock market are influential and forward looking and we in Israel, the R&D capital of cannabis, collaborate with our Canadian friends on many different levels.  I look forward to participating at the WCC as the medicine and business of cannabis develops at breathtaking speed both in Israel and beyond,” said Kaye.


SOURCE iCAN: Israel Cannabis

Continue Reading


Loyalist College to launch Canada’s first Technology Access Centre for natural products and cannabis



Reading Time: 3 minutes


Loyalist College is the recipient of a $1,750,000 Natural Sciences and Engineering Research Council of Canada (NSERC) College and Community Innovation (CCI) Program grant over five years to launch Canada’s first Technology Access Centre (TAC) for natural products and cannabis. In addition, Loyalist received $1Mthrough the Canada Foundation for Innovation’s (CFI) College-Industry Innovation Fund (CIIF) to add specialized equipment to the TAC.

Loyalist was one of 90 recipients at colleges, cégeps and polytechnics across the country to receive part of the $73M in funding, announced today by the Honourable Kirsty Duncan, Minister of Science and Sport, at Georgian College in Barrie, Ontario. Through the CCI Program and the CIIF, this investment will help post-secondary institutions partner directly with local employers to facilitate commercialization and transform the results of research and development into new technologies to help businesses expand and grow.

The rapid growth of Canada’s cannabis, hops and natural products sectors positions Loyalist’s Applied Research Centre for Natural Products and Medical Cannabis (ARC) as a national innovation hub for small- to medium-sized enterprises. As a TAC, Loyalist will build on the ARC’s 15 years of natural product extraction expertise and analysis-based applied research. In transitioning to a TAC, Loyalist’s ARC will significantly increase the College’s capacity to lead applied research of commercially relevant natural products and cannabis, and to support innovation by enhancing industries’ access to sector-relevant expertise and technology.

The TAC initiative will cultivate an environment for College-industry partnerships to thrive while providing students with unparalleled opportunities for work-integrated learning; investigating extraction, isolation, and formulation; and product development. In partnership with the Quinte Economic Development Commission (QEDC), Loyalist will support the Bay of Quinte’s burgeoning natural products and cannabis sectors to generate regional socioeconomic benefits, and to provide opportunities for a new generation of innovators. Loyalist will also offer companies across Canada a supportive, community-oriented platform from which to enhance their productivity, expand their reach and augment their competitiveness in the global market.


“We are very grateful for NSERC’s continued support and proud to be Canada’s first TAC for natural products and cannabis. Loyalist currently has more than 25 companies interested in applied research, and as our ARC transitions into a TAC, we will be able to meet their requirements while significantly extending our network to help more companies to innovate. Our Biosciences and Cannabis Applied Science students will have the advantage of being involved in ground-breaking research that propels Canada forward as the world leader in cannabis and natural product developments.” – Dr. Ann Marie Vaughan, Loyalist College President & CEO

“It’s great to see this NSERC and CFI funding come through for Loyalist College’s launch of Canada’s first TAC for research in natural products and cannabis. Being able to conduct research in a state-of-the-art facility means that students working in the College’s ARC will be able to build up their expertise in product analysis; which can then be applied directly to commercial development. This is just the beginning of seeing a new series of natural products being designed, assessed, made and delivered from our region.” – Neil R. Ellis, Member of Parliament for Bay of Quinte

“I am so proud to see the innovation that is driving research and economic development in our rural community through Loyalist College’s ARC. Innovation is key to Rural Sustainability and this investment will ensure that we are training the next generation in the latest technological advances. I congratulate them on their NSERC and CFI grant, and wish them all the best of success.” – Mike Bossio, Member of Parliament for Hastings—Lennox and Addington

“The Quinte Economic Development Commission is proud to be a supporting partner with Loyalist College on this important initiative that is aligned with economic development opportunities and priorities in the region. The TAC will support industry research and innovation for companies in key industry sectors as well as helping students develop in-demand skills and experience. Congratulations to the team at Loyalist on launching this important project.” – Chris King, Chief Executive Officer, Quinte Economic Development Commission


SOURCE Loyalist College

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us:

© 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania